Though psychotherapy, medications and brain stimulation are used to treat major depressive disorder (MDD), treatment response depends on several individualized clinical factors and frequently requires multiple treatment trials. To guide more effective personalized interventions, there is thus a need to identify biological markers to elucidate the mechanisms of response and to predict treatment outcomes in MDD. Prior evidence suggests neurochemical disturbances in mood-regulating networks, including the anterior cingulate cortex (ACC) and connected prefrontal and subcortical centers, contribute to MDD and have a role in treatment response. 1--4 To identify treatment-related changes in neurochemical markers implicated in MDD, 2,4,5 we applied singlevoxel proton magnetic resonance spectroscopy ( 1 HMRS) for crosssectional and longitudinal analysis of ACC glutamate (Glu), choline (Cho) and N-acetyl aspartate (NAA) in 10 patients with DSM-IVR diagnoses of MDD (mean age: 44.0 years, 7.93 s.d.; 6 females), followed prospectively during index treatment, and 10 demographically similar controls (mean age: 39.03 years, 9.55 s.d.; 6 females). Electroconvulsive therapy (ECT) was used as the therapeutic modality as it is a highly effective procedure for treating severe MDD that elicits rapid response in eligible individuals. 6 Patients were assessed at three time points: baseline and after the second and sixth ECT sessions, corresponding to B48 h and 2 weeks post-treatment initiation (see Supplementary Information for clinical details). The Hamilton (HAMD) and MontgomeryAsberg (MADRS) Depression Rating Scales recorded therapeutic response. Controls were assessed twice, B2 weeks apart, to determine disease effects, normative values and estimate the variance of serial scanning. All subjects, without neurological disorders, alcohol/substance abuse or dementia, provided UCLA Institutional Review Board-approved informed consent. Highresolution T1-weighted MPRAGE structural (FOV: 256; voxel size: 1 mm 3 ; TR/TE: 2200/5.16 ms; flip angle: 121) and single-voxel point resolved spectroscopy (PRESS) acquisitions (TR/TE: 2000/ 30 ms; spectral width 2000 Hz; 1024 points) with (128 averages) and without water suppression (8 averages) were collected on a Siemens 3T Allegra system. Automatic and manual 3D shimming was applied to reduce B0 inhomogeneity for voxels (20 Â 18 Â 12 mm 3 ) placed in midline anterior ACC gray matter ( Figure 1a ; see Supplementary Information). LCModel computed the levels of Glu, Cho and NAA relative to the unsuppressed water signal. Derived metabolites levels were corrected for voxel CSF content using corresponding tissue-classified T1-weighted images. 7 Metabolites (with variances o20%) did not deviate from normality (Kolmogorov--Smirnov test, all P40.50). For baseline comparisons, including age and gender as covariates, main effects of diagnosis were observed for Glu only (F(1, 19) ¼ 8.61, Po0.01 (lower in patients)). General linear mixed models, including metabolites from each time point and a subject variable to control for within-subject correlations, also showed a significant diagnosis by time interaction for Glu (F(1, 21.98) ¼ 4.94, Po0.037). Glu levels increased significantly over time in patients approximating normal levels (F(2, 16.56) ¼ 4.05, Po0.037) but remained stable in controls (P ¼ 0.47). In patients, subsequent pairwise comparisons showed significant Glu elevations between baseline and the sixth ECT (Po0.018). In the absence of overall effects of time, pairwise comparisons in patients also showed significant decreases in NAA (Po0.048) and increases in Cho (Po0.047) between baseline and the sixth ECT (Figure 1b MDD-related reductions in ACC Glu normalize with ECT treatment and associate with clinically determined therapeutic response. Results are in line with prior reports, indicating Glu deficits in MDD 2, 4 and extend earlier observations of increased Glu/glutamine (Glx) in the left ACC in patients treated with ECT, 8 shown here to also mirror clinical response. NAA and Cho, though not discriminating diagnostic groups at baseline, also showed treatment effects in patients. Together, these neurochemical changes suggest treatment-induced neuroplasticity in the structure, density and integrity of mature neurons 9 and/ or may reflect changes relating to adult neurogenesis in connected hippocampal and subventricular regions. 10 Results also support that neurochemical signatures in the ACC may predict future therapeutic response through mechanisms potentially overlapping with other forms of treatment. Studies including additional treatment modalities, larger samples and longer follow-ups with relapse rates may confirm these observations.
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The authors declare no conflict of interest. During pregnancy, maternal folate receptor alpha (FRa) autoantibodies could block folate transfer to the fetus and increase the risk of neural tube defects. 1 The prevalence of blocking FRa antibodies in healthy adult women was estimated at 4 --7% in Spain, 2 9 --13% in Ireland 3 and 10 --15% in the US population.
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A low titer of this antibody in a fraction of the adult population appears to be non-pathologic. Postnatally acquired FR autoantibodies blocking folate transport to the brain have been associated with the infantile-onset cerebral folate deficiency syndrome, 4 which in a number of patients manifests as low-functioning autism with neurological deficits. 5 In a US population with autism spectrum disorder (ASD), either the blocking-or the binding-type autoantibody was detected in 75% of the children and high-dose folinic-acid supplementation improved the core symptoms of autism in these children. 6 We studied a population of infantile autism, non-autistic controls with developmental deficits and their parents in Belgium (research project supported by FNRS Belgium No: 3.4.540.09.F). Serum was tested for FRa-blocking autoantibodies as described previously. 4 Plasma homocysteine and serum folate were also measured. The samples were coded and blinded to all analysis. Table 1 summarizes the results for 75 children with infantile autism and their parents compared with 30 non-autistic controls with developmental delay. A total of 74 mothers of children with autism and 50 fathers were available for testing. Although there was an expected preponderance of males in the autistic group, age and serum folate for both groups were similar, while homocysteine was in the normal range (5 --15 mmol l À1 ). Blocking FR antibodies in autism showed a significantly higher prevalence of 47% compared with only 3.3% in developmentally delayed non-autistic children (Po0.001). In 27 of the 35 autistic children, both parents tested negative, suggesting postnatal development of FR autoimmunity as the likely mechanism. In 8 of the 35 children with positive FR antibodies, either the mother or the father also tested positive, suggesting an additional role of parental antibodies in the pathogenesis. Moreover, in the 40 autistic children testing negative, FR antibodies were present in 10 mothers and 4 fathers, while in three families both parents tested positive. These findings suggest that FR autoimmunity in either one or both parents may contribute to the development of autism in their offspring. Compared with the presence of FR antibodies in only one child with attention deficit hyperactivity disorder and both his parents among the 30 non-autistic controls, the overall results for the autistic population showed a higher prevalence of FR antibodies in 19 mothers and 9 fathers.
Repeated testing of seven autistic children showed wide fluctuations of FRa antibody and two children tested over 6 weeks showed weekly variations ranging from 0 to 1.14 pmol FRablocked per ml serum. Fluctuations in antibody titer seen in most autoimmune disorders may be driven by a multitude of factors, among them, immune stimulation by antigen expression or exposure and antigen --antibody clearance. Free antibody in serum likely represents excess after saturating membrane-bound FRa antigen. Therefore, multiple testing at separate intervals should be done to rule out FR autoimmunity. The short-term effects of rising FR-antibody titers have been correlated with increased aggression and loss of communicative skills. 5 Even in children testing negative, the presence of maternal antibodies may have a role in prenatal brain development and autism. In families where only the father tested positive, the Abbreviations: FR AbÀ: FR autoantibodies testing negative; FR Ab+: FR autoantibodies testing positive; FR, folate receptor; MÀPÀ: both mother and father testing negative; MÀP+: only father testing positive; M+PÀ: only mother testing positive; M+P+: both parents testing positive for antibodies; NS, not significant. The ** and * signs stand for two and one child, respectively, without antibodies whose serum folate was lowered. Among 30 retarded non-autistic children, only one boy with ADHD and learning deficits, as well as both parents, tested positive for FR antibodies.
